Protagonist Therapeutics, Inc
PTGXNasdaqCIK 1377121HealthcareFiscal year ends Dec 31
Reports and events: 164 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-08-0516:17 ET | 10-Q | Quarterly reportPeriod 2026-06-30 | 0001104659-26-091123 |
| 2026-08-0516:11 ET | 8-K | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001104659-26-091099 |
| 2026-06-1816:30 ET | 8-K | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001104659-26-075777 |
| 2026-05-0516:27 ET | 10-Q | Quarterly reportPeriod 2026-03-31 | 0001104659-26-055661 |
| 2026-05-0516:08 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-26-055629 |
| 2026-04-2816:44 ET | DEF 14A | Proxy statementPeriod 2026-06-17 | 0001104659-26-050429 |
| 2026-02-2516:28 ET | 10-K | Annual reportPeriod 2025-12-31 | 0001104659-26-019696 |
| 2026-02-2516:08 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-26-019658 |
| 2026-01-1208:00 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001104659-26-002724 |
| 2025-11-0616:52 ET | 10-Q | Quarterly reportPeriod 2025-09-30 | 0001104659-25-107816 |
| 2025-11-0616:19 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-25-107753 |
| 2025-08-0616:22 ET | 10-Q | Quarterly reportPeriod 2025-06-30 | 0001558370-25-010534 |
| 2025-08-0616:12 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-25-074719 |
| 2025-06-2616:08 ET | 8-K | 5.07 Shareholder vote results | 0001104659-25-063038 |
| 2025-05-0617:04 ET | 10-Q | Quarterly reportPeriod 2025-03-31 | 0001558370-25-006530 |
| 2025-05-0616:27 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-25-045073 |
| 2025-04-2916:05 ET | DEF 14A | Proxy statementPeriod 2025-06-20 | 0001104659-25-041206 |
| 2025-03-2016:12 ET | 8-K | 8.01 Other events | 0001104659-25-026135 |
| 2025-03-1117:17 ET | 8-K/A | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-25-022615 |
| 2025-03-1008:17 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-25-021986 |
| 2025-03-0308:18 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-25-019516 |
| 2025-02-2116:36 ET | 10-K | Annual reportPeriod 2024-12-31 | 0001558370-25-001317 |
| 2025-02-2107:07 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-25-015897 |
| 2025-01-0616:05 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001104659-25-001304 |
| 2024-11-1816:36 ET | 8-K | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-24-120165 |
| 2024-11-0716:39 ET | 10-Q | Quarterly reportPeriod 2024-09-30 | 0001558370-24-014888 |
| 2024-11-0716:09 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-24-115303 |
| 2024-09-2016:05 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001104659-24-101688 |
| 2024-08-0616:18 ET | 10-Q | Quarterly reportPeriod 2024-06-30 | 0001558370-24-011095 |
| 2024-08-0607:08 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-24-086088 |
| 2024-06-2616:12 ET | 8-K | 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001104659-24-075162 |
| 2024-05-0716:51 ET | 10-Q | Quarterly reportPeriod 2024-03-31 | 0001558370-24-007081 |
| 2024-05-0716:29 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-24-058036 |
| 2024-04-2616:31 ET | DEF 14A | Proxy statementPeriod 2024-06-20 | 0001104659-24-052999 |
| 2024-02-2716:33 ET | 10-K | Annual reportPeriod 2023-12-31 | 0001558370-24-001850 |
| 2024-02-2716:12 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-24-028208 |
| 2024-01-3116:05 ET | 8-K | 1.01 Entry into a material agreement | 0001104659-24-008787 |
| 2024-01-1608:01 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-24-003903 |
| 2024-01-0808:00 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001104659-24-002073 |
| 2023-11-0217:07 ET | 10-Q | Quarterly reportPeriod 2023-09-30 | 0001558370-23-017460 |
| 2023-11-0216:40 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-23-113828 |
| 2023-10-3016:30 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001104659-23-112592 |
| 2023-08-0316:21 ET | 10-Q | Quarterly reportPeriod 2023-06-30 | 0001558370-23-013245 |
| 2023-08-0316:13 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-23-087269 |
| 2023-07-0508:00 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-23-077821 |
| 2023-07-0316:06 ET | 8-K | 3.01 Delisting notice | 0001104659-23-077599 |
| 2023-05-3016:20 ET | 8-K | 5.07 Shareholder vote results | 0001104659-23-066057 |
| 2023-05-0416:33 ET | 10-Q | Quarterly reportPeriod 2023-03-31 | 0001558370-23-008137 |
| 2023-05-0416:18 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-23-056018 |
| 2023-04-1216:02 ET | DEF 14A | Proxy statementPeriod 2023-05-25 | 0001104659-23-044557 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 27, 2026, 17:29 ET. Listed shows no prices and gives no investment advice.